The Zero100 Podcast • July 14, 2025

Novo Nordisk & Eli Lilly: Manufacturing Lessons from the GLP-1 Giants

As GLP-1 drugs like Ozempic and Zepbound took the world by storm, Novo Nordisk and Eli Lilly faced a massive question: how do you fill the need at maximum speed? We pull back the curtain on the strategies that allowed both companies to scale their manufacturing and cement market dominance, offering takeaways for any leader navigating unprecedented demand.

Listen to this episode on Spotify | Apple | Amazon |

Resilience

Podcast

In this Episode

Caroline Chumakov

Principal Analyst, Zero100

Jenna Fink

Principal Analyst, Zero100

About the Show

Welcome to The Zero100 Podcast, the “unboring” supply chain podcast. Each week, Zero100's researchers, analysts, and data scientists deliver sharp takes on the news, delve into new research, and interview leaders at the forefront of supply chain’s digital revolution, giving you the insights you need to drive growth and resilience.